NCT06690697 2024-11-15
Combination of Toripalimab and JS004 Therapy for ccRCC
Fudan University
Phase 2 Recruiting
Clinical Trials
52 trialsNCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT00606866 2023-11-29
MRI
University of Chicago
Phase 3 Completed
NCT00496756 2023-10-26
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
University of Nebraska
Phase 2 Terminated
NCT00392821 2022-06-06
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00589420 2022-02-17
Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT01444807 2021-09-17
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT02406521 2020-03-04
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01497444 2020-02-06
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT00727532 2019-05-03
Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Northwestern University
Phase NA Terminated
NCT01844947 2019-04-26
VINSOR
Karolinska University Hospital
Phase 1 Completed
NCT01731158 2019-02-06
BERAT
Central European Society for Anticancer Drug Research
Phase 2 Completed
NCT00924807 2018-12-11
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
Beth Israel Medical Center
Phase 1/2 Terminated
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT03456401 2018-03-07
TOKIO
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT00461851 2017-12-14
Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
Yale University
Phase 2 Completed
NCT00703638 2017-11-29
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00466752 2017-11-22
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
University of Washington
Phase 2 Completed
NCT02122003 2017-11-22
SOAP
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT01189370 2017-06-01
Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
University of Kansas Medical Center
Phase 2 Completed
NCT02330783 2017-05-09
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT00405366 2017-04-18
NRR
UNC Lineberger Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT01005797 2017-03-03
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
Medical University of South Carolina
Phase 1 Completed
NCT00418496 2017-02-20
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00445042 2016-03-17
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00448149 2016-03-17
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase 1/2 Completed
NCT00714948 2015-11-16
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01342627 2015-10-06
SERCC
Centro di Riferimento Oncologico - Aviano
Phase 2 Terminated
NCT01100242 2015-09-17
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00609934 2015-07-23
Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone
University Health Network, Toronto
Phase 1/2 Completed
NCT00854620 2015-06-19
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
Stanford University
Phase 2 Completed
NCT00589550 2015-06-08
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Terminated
NCT00694291 2015-03-06
Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT00544609 2014-10-02
SOGUG-07-01
Spanish Oncology Genito-Urinary Group
Phase 1 Completed
NCT00384969 2014-08-18
Sorafenib and RAD001 Renal Cell Carcinoma
University of California, San Francisco
Phase 1 Completed
NCT00866320 2014-07-23
Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00424385 2014-07-21
Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)
Oncology Specialists, S.C.
Phase 1 Completed
NCT00414388 2014-04-07
Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer
Oncology Specialists, S.C.
Phase 1/2 Completed
NCT00602862 2013-12-02
Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
Radboud University Medical Center
Phase NA Completed
NCT00557830 2013-07-18
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Accelerated Community Oncology Research Network
Phase 2 Terminated
NCT00635791 2013-06-20
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
University of Colorado, Denver
Phase 1 Completed
NCT01616186 2013-04-08
Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
University of California, San Francisco
Phase 2 Withdrawn
NCT00452387 2011-09-16
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
Accelerated Community Oncology Research Network
Phase 2 Terminated
NCT01215266 2011-09-08
Sorafenib in Urothelium Cancer of Bladder
Association of Urologic Oncology (AUO)
Phase 2 Terminated
NCT00478114 2011-08-29
Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
Mahidol University
Phase 3 Completed
NCT01230697 2010-10-29
SORHORM
University of Turin, Italy
Unknown
NCT00848640 2010-05-26
MERITS
Egyptian Foundation For Cancer Research
Phase 2 Completed
NCT00609401 2009-02-26
ROSORC
Italian Trial in Medical Oncology
Phase 2 Completed
NCT00619996 2009-02-26
P1
Italian Trial in Medical Oncology
Phase 2 Completed